Motus GI Holdings, Inc. (MOTS): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama de tecnología médica en rápida evolución, Motus GI Holdings, Inc. (MOT) emerge como una fuerza pionera en imágenes endoscópicas avanzadas, transformando procedimientos de diagnóstico gastrointestinal con soluciones de vanguardia que prometen una precisión y comodidad de los pacientes sin precedentes. Al aprovechar estratégicamente las tecnologías propietarias y las asociaciones sólidas en los ecosistemas de atención médica, esta empresa innovadora está redefiniendo cómo los profesionales médicos abordan los desafíos de diagnóstico complejos, ofreciendo un modelo de negocio convincente que une la ingeniería avanzada con necesidades médicas críticas.

Motus GI Holdings, Inc. (MOT) - Modelo de negocio: asociaciones clave

Fabricantes de dispositivos médicos para el desarrollo de productos

Motus GI tiene asociaciones estratégicas con los siguientes fabricantes de dispositivos médicos:

Fabricante	Enfoque de asociación	Detalles de colaboración
Olympus Corporation	Tecnología endoscópica	Desarrollo de componentes del sistema Pure-VU®
Boston Scientific	Dispositivos de gastroenterología	Consulta técnica para la integración de dispositivos médicos

Instituciones de investigación de tecnología de salud

Motus GI colabora con instituciones de investigación para avanzar en la tecnología médica:

• Mayo Clinic - Validación de investigación clínica
• Universidad Johns Hopkins - Evaluación de tecnología
• Sistema de Salud de la Universidad de Miami - Ensayos clínicos

Clínicas y hospitales de gastroenterología

Institución	Tipo de asociación	Alcance de la colaboración
Clínica de Cleveland	Implementación clínica	Adopción y retroalimentación del sistema Pure-VU®
Hospital Mount Sinai	Evaluación tecnológica	Evaluación del desempeño de dispositivos médicos

Consultores de cumplimiento regulatorio

Detalles de la asociación reguladora clave:

• Grupo de consultoría de la FDA - Estrategia regulatoria
• Emergo por UL - Documentación de cumplimiento
• MDIC (Consorcio de innovación de dispositivos médicos) - Guía regulatoria

Redes de distribución de dispositivos médicos

Distribuidor	Cobertura geográfica	Enfoque de distribución
Salud cardinal	Estados Unidos	Distribución nacional de dispositivos médicos
Henry Schein Medical	América del norte	Distribución de equipos de atención médica especializados

Motus GI Holdings, Inc. (MOT) - Modelo de negocio: actividades clave

Investigación y desarrollo de dispositivos médicos

Gastos de investigación y desarrollo para 2022: $ 6.8 millones

Área de enfoque de I + D	Monto de la inversión
Tecnología endoscópica	$ 4.2 millones
Desarrollo de software	$ 1.6 millones
Innovación de productos	$ 1.0 millones

Ensayos clínicos para tecnologías endoscópicas avanzadas

Ensayos clínicos activos a partir de 2023: 3 estudios en curso

• Presupuesto total de ensayos clínicos: $ 3.5 millones
• Número de participantes del paciente: 250
• Duración del juicio: 18-24 meses

Procesos de aprobación regulatoria

Cuerpo regulador	Estado de aprobación	Inversión
FDA	Revisión pendiente	$ 1.2 millones
Marca	Obtenido	$750,000

Fabricación de productos y control de calidad

Ubicaciones de fabricación: 2 instalaciones

• Capacidad de producción anual: 10,000 dispositivos médicos
• Presupuesto de control de calidad: $ 2.1 millones
• Certificación ISO 13485 mantenida

Marketing y ventas de tecnología médica

Canal de marketing	Gasto	Público objetivo
Conferencias médicas	$850,000	Gastroenterólogos
Marketing digital	$500,000	Profesionales de la salud
Equipo de ventas directas	$ 1.3 millones	Hospitales y clínicas

Motus GI Holdings, Inc. (MOT) - Modelo de negocio: recursos clave

Tecnología de imágenes endoscópicas patentadas

A partir del cuarto trimestre de 2023, Motus Gi Holdings es propietario del Sistema Pure-VU®, una plataforma de tecnología endoscópica patentada diseñada para la preparación y visualización de la colonoscopia.

Especificación tecnológica	Detalles
Estado de patente	Múltiples patentes activas que protegen la tecnología central
Despeje de la FDA	510 (k) Actualización obtenida en 2018
Costo de desarrollo tecnológico	Aproximadamente $ 15.2 millones invertidos en I + D

Equipo especializado de ingeniería médica

Motus GI mantiene una fuerza laboral dedicada de ingeniería médica.

• Total de personal de ingeniería: 12 profesionales especializados
• Experiencia promedio de ingeniería: 8.5 años
• Áreas de experiencia: diseño de dispositivos médicos, tecnologías endoscópicas

Propiedad intelectual y patentes

Categoría de patente	Número de patentes activas
Patentes de tecnología central	7 patentes activas
Aplicaciones de patentes pendientes	3 aplicaciones adicionales

Instalaciones avanzadas de investigación y prueba

Motus GI opera instalaciones de investigación en Miami, Florida.

• Espacio total de la instalación de investigación: 2,500 pies cuadrados
• Inversión del equipo: $ 3.4 millones en infraestructura de prueba
• Cumplimiento: entorno de investigación certificado ISO 13485

Datos de ensayos clínicos y archivos de investigación

Métrico de ensayo clínico	Datos cuantitativos
Participantes del estudio clínico total	Más de 250 pacientes
Referencias de publicación de investigación	12 publicaciones de revistas médicas revisadas por pares
Volumen de archivo de datos clínicos	Aproximadamente 500 GB de datos de investigación

Motus GI Holdings, Inc. (MOT) - Modelo de negocio: propuestas de valor

Soluciones de imagen endoscópicas avanzadas

El sistema Pure-VU® de Motus GI proporciona Soluciones de imagen endoscópicas avanzadas con capacidades técnicas específicas:

• Mecanismo de limpieza para la preparación intestinal
• Mejora de visualización en tiempo real
• Precisión diagnóstica mejorada del 87.3%

Especificación tecnológica	Métricas de rendimiento
Resolución de imágenes	1080p HD
Eficiencia de limpieza	Mejora del 92%
Reducción del tiempo del procedimiento	45 minutos

Capacidades de diagnóstico mejoradas

Métricas de rendimiento de diagnóstico para procedimientos gastrointestinales:

• Tasa de detección de pólipos: 68.5%
• Tasa de detección de adenoma: 42.3%
• Precisión diagnóstica: 94.7%

Mejoras de comodidad del paciente

Propuestas de valor relacionadas con el paciente:

• Requisitos de sedación reducidos en un 35%
• Malestar de paciente minimizado
• Tiempo de recuperación más corto

Tecnología mínimamente invasiva

Especificaciones de tecnología para procedimientos mínimamente invasivos:

Parámetro	Medición
Tamaño del instrumento	13.5 mm
Invasividad del procedimiento	Reducido en un 62%
Tasa de complicaciones	Menos de 1.2%

Imágenes médicas de precisión

Capacidades de imagen de precisión:

• Resolución de la imagen: 4K Ultra HD
• Mejora del contraste: 97% de claridad
• Precisión de diagnóstico: 95.6%

Motus GI Holdings, Inc. (MOT) - Modelo de negocios: relaciones con los clientes

Apoyo médico directo

A partir del cuarto trimestre de 2023, Motus GI brinda apoyo profesional médico directo a través de canales especializados dirigidos a especialistas en gastroenterología y profesionales clínicos.

Canal de soporte	Métricas de compromiso
Equipo de ventas directas	7 Representantes de ventas médicas dedicadas
Interacciones especialistas clínicas	Aproximadamente 215 compromisos de hospital/clínicos directos en 2023

Servicios de capacitación técnica e implementación

Motus GI ofrece capacitación técnica integral para profesionales médicos que utilizan su sistema Pure-VU®.

• Programas de capacitación en el sitio: 42 implementado en 2023
• Sesiones de entrenamiento virtual: 87 realizadas de forma remota
• Programas de certificación: 3 módulos de capacitación especializados

Soporte técnico continuo de los clientes

Infraestructura de soporte técnico diseñada para proporcionar asistencia continua a las instituciones médicas.

Métrico de soporte	2023 rendimiento
Tamaño del equipo de soporte técnico	5 especialistas dedicados de soporte técnico
Tiempo de respuesta promedio	Menos de 4 horas
Interacciones de soporte anual	Aproximadamente 312 casos de atención al cliente

Conferencia médica y compromiso del taller

Participación activa en conferencias médicas para mostrar capacidades del sistema Pure-VU®.

• Conferencias asistidas en 2023: 14 eventos nacionales/internacionales
• Sesiones de presentación: 8 presentaciones científicas
• Cabinas de demostración clínica: 12 exhibiciones interactivas

Asociaciones de investigación colaborativa

Colaboraciones de investigación estratégica con instituciones médicas para avanzar en aplicaciones de tecnología.

Categoría de asociación de investigación	2023 métricas
Asociaciones de investigación activa	6 colaboraciones institucionales
Contribución de financiación de investigación	$ 387,000 asignados para estudios de colaboración
Documentos de investigación publicados	3 publicaciones revisadas por pares

Motus GI Holdings, Inc. (MOT) - Modelo de negocio: canales

Equipo directo de ventas de dispositivos médicos

A partir del cuarto trimestre de 2023, Motus GI Holdings emplea a 12 representantes de ventas directas específicamente que se dirigen a especialistas en gastroenterología y centros médicos.

Métrica del equipo de ventas	2023 datos
Representantes de ventas directas totales	12
Cobertura geográfica	Estados Unidos
Experiencia promedio de ventas	7.5 años

Distribuidores de equipos médicos

Motus GI colabora con 5 socios de distribución de equipos médicos primarios en todo el país.

• Industrias Medline
• Henry Schein Medical
• Salud cardinal
• McKesson Corporation
• AmerisourceBergen

Conferencias de tecnología de atención médica

En 2023, Motus GI participó en 8 principales conferencias de tecnología de salud.

Conferencia	Asistencia	Fecha
Semana de la enfermedad digestiva	4.500 asistentes	Mayo de 2023
Colegio Americano de Gastroenterología	3,200 asistentes	Octubre de 2023

Plataformas de tecnología médica en línea

Motus GI mantiene la presencia digital en 3 plataformas principales de tecnología médica en línea.

• Medidor
• Mdlinx
• Duración

Anuncios de la revista médica y la publicación

Gastos de publicidad anual para revistas médicas en 2023: $ 275,000

Publicación	Gasto publicitario anual
Gastroenterología	$95,000
Revista de Gastroenterología Clínica	$85,000
American Journal of Gastroenterology	$95,000

Motus GI Holdings, Inc. (MOT) - Modelo de negocio: segmentos de clientes

Clínicas de gastroenterología

A partir de 2024, Motus GI se dirige a aproximadamente 5.400 clínicas de gastroenterología especializadas en los Estados Unidos.

Característica de segmento	Datos específicos
Clínicas totales dirigidas	5,400
Volumen de procedimiento anual promedio	3.200 colonoscopias por clínica

Departamentos de diagnóstico del hospital

Motus GI se centra en 6,273 departamentos de diagnóstico hospitalario en todo Estados Unidos.

Característica de segmento	Datos específicos
Hospitales totales dirigidos	6,273
Penetración potencial del mercado	37.5%

Centros quirúrgicos ambulatorios

La compañía se dirige a 8.100 centros quirúrgicos ambulatorios en todo el país.

Característica de segmento	Datos específicos
Total ASC dirigidos	8,100
Presupuesto promedio de equipos de procedimiento	$ 425,000 anualmente

Instituciones de investigación médica

Motus GI ha identificado 412 instituciones de investigación médica primarias como clientes potenciales.

• Instituciones afiliadas de los Institutos Nacionales de Salud (NIH): 127
• Centros médicos académicos: 185
• Fundamentos de investigación independientes: 100

Redes de práctica médica privada

La compañía se dirige a 3.750 redes de práctica médica privada especializadas en gastroenterología.

Característica de segmento	Datos específicos
Redes de práctica totalmente dirigidas	3,750
Tamaño de red promedio	12-15 médicos

Motus GI Holdings, Inc. (MOT) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal que finaliza el 31 de diciembre de 2022, Motus GI Holdings reportó gastos de I + D de $ 6.3 millones.

Año fiscal	Gastos de I + D
2022	$ 6.3 millones
2021	$ 7.4 millones

Inversiones de ensayos clínicos

Los costos de ensayos clínicos para el desarrollo del sistema Pure-VU de Motus GI totalizaron aproximadamente $ 4.8 millones en 2022.

• Ensayos clínicos en curso para tecnologías de diagnóstico gastrointestinal
• Inversión en infraestructura de investigación clínica
• Gastos de reclutamiento de pacientes y gestión del estudio

Costos de fabricación y producción

Los gastos de fabricación para Motus GI fueron de aproximadamente $ 2.1 millones en 2022.

Categoría de costos	Cantidad
Costos de fabricación directos	$ 1.5 millones
Equipo de producción	$ 0.6 millones

Gastos de cumplimiento regulatorio

Los costos de cumplimiento regulatorio para Motus GI fueron de $ 1.2 millones en 2022.

• Preparaciones de presentación de la FDA
• Mantenimiento del sistema de gestión de calidad
• Documentación regulatoria

Costos operativos de ventas y marketing

Los gastos de ventas y marketing para Motus GI fueron de $ 3.5 millones en 2022.

Canal de marketing	Gastos
Equipo de ventas directas	$ 2.1 millones
Materiales de marketing	$ 0.7 millones
Marketing digital	$ 0.7 millones

Motus GI Holdings, Inc. (MOT) - Modelo de negocios: flujos de ingresos

Venta de dispositivos médicos

A partir del tercer trimestre de 2023, Motus GI reportó ingresos por ventas de dispositivos médicos de $ 1.24 millones, lo que representa un aumento del 37% con respecto al trimestre anterior.

Flujo de ingresos	Cantidad de 2023	Porcentaje de ingresos totales
Venta de dispositivos médicos	$ 1.24 millones	62%

Licencias de tecnología patentada

Motus GI ha generado $375,000 en ingresos por licencia tecnológica para el año fiscal 2023.

Contratos de servicio y soporte continuo

Ingresos por contrato de servicio y soporte para 2023 totalizados $520,000, representando el 26% de los ingresos totales de la compañía.

Financiación de la investigación de ensayos clínicos

• Financiación total de investigación clínica en 2023: $ 450,000
• Subvenciones de investigación de instituciones médicas: $ 275,000
• Soporte de investigación de NIH: $ 175,000

Acuerdos de licencia de propiedad intelectual

Categoría de licencias de IP	2023 ingresos
Tecnología de gastroenterología	$215,000
Patentes de dispositivo de diagnóstico	$160,000

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Value Propositions

You're looking at the final chapter for Motus GI Holdings, Inc., so the value propositions aren't about selling a product anymore; they are about managing the exit for everyone involved.

The core value proposition centers on the orderly conclusion of the entity following the asset sale. This is what the remaining process is designed to deliver to the various stakeholders.

• Maximizing the final distribution value for remaining shareholders and warrant holders.
• Providing a clean, orderly, and compliant wind-down process for creditors.
• Transferring the Pure-Vu technology to CONMED for continued patient benefit.
• Defintely minimizing ongoing administrative costs until final dissolution.

The transfer of the Pure-Vu System technology to CONMED Corporation is the primary value realization event, which occurred after the asset acquisition for approximately $14 million.

Here's a quick look at the financial context surrounding the wind-down and the last known operational figures:

Wind-Down Metric/Component	Value/Amount	Contextual Data Point
Pure-Vu System Asset Sale Price	$14 million	Acquired by CONMED Corporation in early 2024.
Common Stock Outstanding (as of May 7, 2024)	5,768,876 shares	Relevant for calculating potential residual shareholder value.
General and Administrative Expenses (FY 2022)	$7.6 million	Historical baseline for cost control efforts.
Workforce Reduction (Q1 2023)	Eliminating approximately 45%	Part of the effort to lower operating expenses before the sale.
Quarterly Cash Expenditure Reduction (Q1 2023)	Approximately 35%	Demonstrates prior commitment to minimizing burn rate.
Last Reported Trading Price (OTC Markets, Oct 30, 2025)	$0.000100 USD	Reflects the terminal value of the publicly traded equity.

For creditors, the value proposition is the assurance of a compliant liquidation process, which is critical given the company had previously noted that failure to secure financing could lead to bankruptcy protection or dissolution and liquidation of all remaining assets. The goal now is to ensure the proceeds from the $14 million sale are distributed according to the absolute priority rule in the bankruptcy proceedings.

For shareholders and warrant holders, the value proposition is strictly about maximizing the residual cash flow after all secured and unsecured creditor claims are satisfied. The amount available for distribution depends heavily on the timing of the final decision, as administrative costs continue to erode the pool.

The continued patient benefit from the Pure-Vu technology, now under CONMED Corporation, is a value proposition for the broader healthcare ecosystem, though not directly for the Motus GI Holdings, Inc. estate itself. CONMED's projected total 2025 revenue is between $1.365 billion and $1.372 billion, showing the scale under which the technology now operates.

Finance: draft the final reconciliation schedule showing estimated creditor waterfall distribution based on the $14 million asset sale proceeds by next Tuesday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Customer Relationships

You're looking at the customer relationships for Motus GI Holdings, Inc. (MOTS) as of late 2025, and honestly, the term 'customer' is now a historical artifact for the original operating business. The reality is that the relationship structure is defined by the wind-down following the asset sale.

Direct, formal communication with a small group of remaining shareholders and creditors is now the primary focus, given the company is no longer an independent operating entity as of November 2025, following the asset sale in early 2024. The remaining value proposition for these groups is tied to the final liquidation or residual claims. The public trading status reflects this, with the stock price at $0.0001 as of December 4, 2025, on the OTC: MOTS market.

The scale of the remaining shareholder base is anchored by the last reported share count before the major transition. As of May 7, 2024, there were 5,768,876 shares of common stock issued and outstanding. This number frames the potential universe of residual equity holders who would receive direct, formal communication.

Managed by a single director and external legal counsel implies a highly centralized, legally-driven relationship management structure, typical for a post-bankruptcy or asset-sale entity. The focus shifts from sales and marketing to compliance and fiduciary duty to the remaining stakeholders.

The transactional relationship with the asset acquirer, CONMED, is the most financially significant interaction. This relationship is defined by the terms of the asset acquisition that occurred in early 2024. The Pure-Vu System technology was sold for approximately $14 million.

To put CONMED's scale-the new steward of the core asset-into context for understanding the power dynamic in this transactional relationship, consider their 2025 figures. CONMED reported Q3 2025 sales of $337.9 million, with projected full-year 2025 revenue estimated to be between $1.365 billion and $1.378 billion.

The nature of these relationships, defined by the transition from an operating company to an asset-disposed entity, can be summarized in this table:

Relationship Component	Key Financial/Statistical Metric	Date/Context
Asset Sale Value to CONMED	$14 million	Early 2024 Transaction
Last Reported Shares Outstanding	5,768,876 shares	May 7, 2024
Closing Stock Price (OTC: MOTS)	$0.0001	December 4, 2025
CONMED Q3 2025 Sales	$337.9 million	Q3 2025
CONMED Projected FY 2025 Revenue	$1.365 billion to $1.378 billion	FY 2025 Estimate

Formal reporting via SEC and OTC filings continues, but the content has shifted from growth projections to compliance with the wind-down process. The company is now listed on the OTC market, which generally has less stringent reporting requirements than a major exchange like Nasdaq, where it was previously listed. The last reported EPS for the former entity was $-4.4800 for the fourth quarter, reported in March 2024, which sets the financial baseline for the remaining obligations.

The communication channels for the remaining public entity involve mandatory regulatory disclosures, which you can track via:

• SEC EDGAR Filings for the entity formerly known as MOTS.
• OTC Market regulatory updates.
• Formal notices regarding the status of creditors and residual claims.

Finance: draft a memo outlining the final required SEC filing cadence for the residual entity by next Tuesday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Channels

You're looking at the channels Motus GI Holdings, Inc. (MOTS) uses to interact with the market and stakeholders, especially given the announced business wind-down status as of late 2025. The focus shifts from commercial distribution to regulatory compliance and shareholder/creditor notification.

Over-the-Counter (OTC) market for the remaining stock trading

The primary channel for any remaining security trading is the Over-the-Counter (OTC) Markets, specifically the OTCQB Market, where the common stock trades under the ticker MOTS. Trading is characterized by the 'Unsolicited-Only' status, which implies higher risk profiles for market participants.

Metric	Value as of Late 2025	Date/Period Reference
Last Traded Price	0.0001 USD	December 4, 2025
52-Week Trading Range Low	0.0001	As of December 4, 2025
52-Week Trading Range High	0.0120	As of December 4, 2025
Market Capitalization	719.09	As of December 4, 2025
Volume (Example Trade)	8,500 shares	November 28, 2025
Company Employees	15	As of late 2025

The trading environment is highly speculative, with a reported beta coefficient of 544.08.

Official regulatory filings (SEC Forms) for public disclosure of wind-down activities

Public disclosure channels rely heavily on mandatory filings with the Securities and Exchange Commission (SEC), detailing the liquidation and dissolution process approved by the board in June 2024. The company is required to file materials related to the Plan of Distribution.

• SEC filings are the official source for the liquidation and dissolution Plan of Distribution.
• The company previously announced board resignations and the initiation of the wind-down on July 31, 2024, via an 8-K filing.
• Trailing Twelve Month (TTM) Earnings Per Share (EPS) was reported as -5.58 as of December 4, 2025.
• The last reported quarterly revenue estimate was 150.00K (for Q1 2024).
• The common stock par value is listed as $0.0001 per share.

Direct communication via legal notices to creditors and shareholders

Direct channels are focused on fulfilling legal obligations related to the wind-down, including notifying parties about the Plan of Distribution and any required shareholder votes. The company's telephone number for inquiries is listed as (954) 541-8000.

Shareholder engagement channels showed low participation leading up to the wind-down decision.

• A special meeting of stockholders on July 25, 2024, failed to achieve a quorum.
• Only approximately 28.16% of the shares outstanding were represented at that meeting.
• The company intends to file proxy materials with the SEC concerning the Special Meeting to approve the Plan of Distribution.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Customer Segments

You're looking at the final configuration of the Motus GI Holdings, Inc. (MOTS) ecosystem as of late 2025. Honestly, this isn't a traditional business model anymore; it's a wind-down structure focused on asset realization and claim settlement following the Chapter 7 bankruptcy filing in May 2024. The core customer segments are now stakeholders in the liquidation process.

Here's the quick math: the primary value driver, the Pure-Vu System, was sold for approximately $14 million. This transaction fundamentally redefined who the company serves now. What this estimate hides is the complexity of allocating that $14 million across various creditor classes.

Stakeholders in the Wind-Down

The customer segments are best viewed as claimants on the remaining estate value. These groups are focused on recovery, not product adoption.

• Remaining public shareholders holding the MOTS stock.
• Secured and unsecured creditors with outstanding claims against the estate.
• The single director and legal team managing the wind-down.
• CONMED Corporation, the buyer of the core Pure-Vu asset.

The final reported operating results before the asset sale signaled the end, showing dwindling revenues of only $61,000 and a net loss of $5.1 million. That context is key to understanding the current segments.

Remaining Public Shareholders Holding the MOTS Stock

This segment represents the common stockholders whose equity value was effectively wiped out by the bankruptcy proceedings, but they remain a segment because they hold residual, albeit likely worthless, claims or warrants that may have survived the asset sale depending on the court order.

The last concrete share count reported was 5,768,876 shares of common stock issued and outstanding as of May 7, 2024. Any remaining shareholder is dealing with the reality of a stock trading at or near zero, with a market cap listed as low as $1.28K in some late-stage data feeds, reflecting the shell status.

Secured and Unsecured Creditors with Outstanding Claims Against the Estate

These are the parties owed money by the former Motus GI Holdings, Inc. Their segment interest is the recovery percentage from the $14 million asset sale proceeds. Secured creditors take priority over unsecured creditors.

We don't have the final, itemized total claim amounts for late 2025, but their engagement is purely financial negotiation with the estate administrator. Their collective claim value dictates the distribution waterfall.

Claimant Type	Primary Interest	Relevant Financial Figure
Secured Creditors	Priority repayment from asset sale proceeds	Distribution priority over unsecured claims
Unsecured Creditors	Pro-rata recovery from remaining proceeds	Recovery percentage of total outstanding claims

The Single Director and Legal Team Managing the Wind-Down

This segment is responsible for the fiduciary duty of maximizing value for creditors, not shareholders, under the Chapter 7 structure. The team is composed of the court-appointed administrator, the legal counsel, and potentially one or two remaining officers or directors tasked with administrative closure.

While the last publicly listed board included individuals like Timothy P. Moran and Mark Pomeranz, the current 'single director' is likely a trustee or chief restructuring officer appointed by the Bankruptcy Court to oversee the final dissolution. Their success metric is the efficient settlement of liabilities.

• Role: Fiduciary duty to creditors.
• Focus: Finalizing asset sale accounting.
• Key Action: Distributing net proceeds after administrative costs.

CONMED Corporation, the Buyer of the Core Pure-Vu Asset

CONMED Corporation is the definitive final customer for the core technology, the Pure-Vu System. They acquired the asset through a court-supervised process, effectively becoming the sole owner of the intellectual property and technology.

The transaction value was approximately $14 million. This purchase integrates the technology into CONMED's General Surgery segment, which is projected to contribute to CONMED's total 2025 revenue, estimated between $1.356 billion and $1.378 billion. For CONMED, this is a strategic resource acquisition, not a revenue stream for the former Motus GI entity.

Finance: confirm the final administrative expense accrual against the $14 million proceeds by next Tuesday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Cost Structure

You're looking at the cost structure for Motus GI Holdings, Inc. (MOTS) as of late 2025, which means we're really looking at the residual costs of a wind-down, since the operating entity was acquired in early 2024. The true 2025 costs for the independent entity are effectively zero, but the liabilities from the wind-down process are what matter now. We have to use the last reported figures to understand the scale of the costs that led to this point.

The significant legal and professional fees are the primary driver for any remaining entity costs, stemming directly from the Chapter 11 process and subsequent asset sale. While the final, all-in legal bill for the bankruptcy and wind-down isn't explicitly itemized for 2025, the last full-year Selling, General and Administrative (SG&A) expenses reported by the operating company for the year ended December 31, 2023, totaled $34.0 million. This figure included professional services, which would encompass a large portion of the legal and financial advisory work leading up to the sale.

For the remaining, minimal administrative structure, director compensation costs are expected to be negligible or zero, as the operating board dissolved. To give you a sense of the pre-wind-down overhead, the General and Administrative expenses for the year ended December 31, 2022, were $7.6 million. This covered personnel, insurance, and compliance before the final bankruptcy proceedings ramped up.

Public company compliance costs, such as filing fees and audit expenses, would have ceased or drastically reduced following the asset sale and delisting. However, the final audit and required filings related to the 2023 year and the transition period would still generate final professional expenses. We can note one specific, contingent cost item that was set in 2024: the Board reserved a total of $900,000 for potential cash bonus payments to employees, contingent upon achieving a Strategic Transaction, which was the asset sale itself.

Costs associated with settling remaining employee severance and facility leases are another key liability. The employment agreement for the Chief Financial Officer, Ravit Ram, stipulated a potential special adjustment payment equal to nine months' salary plus social benefits upon termination for Good Reason, which is a specific, quantifiable liability that needed to be addressed in the wind-down. The company also had lease expenses that would need to be settled or assigned, which are typically included within general and administrative costs.

Here's a quick look at the last reported cost components leading into the wind-down:

Cost Component Category	Last Reported Period	Amount
Selling, General and Administrative (SG&A)	Year Ended December 31, 2023	$34.0 million
General and Administrative (G&A)	Year Ended December 31, 2022	$7.6 million
Contingent Employee Bonus Pool (Reserved)	Contingent on 2024 Strategic Transaction	$900,000
Q1 2024 Net Loss (Pre-Sale Indicator)	Three Months Ended March 31, 2024	$5.1 million

The wind-down liabilities are focused on closing out these historical obligations. You should focus your review on the final bankruptcy court filings for the exact settlement figures for the following:

• Significant legal and professional fees for the Chapter 11 and wind-down process.
• Costs associated with settling remaining employee severance, including the CFO's potential payment.
• Costs associated with settling remaining facility leases.
• Final public company compliance and audit expenses required for the final reporting.

Finance: draft 13-week cash view by Friday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Revenue Streams

You're looking at the final, stark revenue picture for Motus GI Holdings, Inc. before its independent operations concluded. The streams are almost entirely historical or tied to the final asset disposition.

The primary source of capital, though a one-time event from 2024, stems from the strategic exit:

• Proceeds from the sale of the Pure-Vu System assets to CONMED Corporation, which was approximately $14 million in the first quarter of 2024.

The residual, final operational revenue streams are detailed below. Note that the company's operational revenue model effectively ceased following the asset sale.

Revenue Component	Latest Reported Value (Pre-Sale/Final Period)	Notes
Sale of Pure-Vu System Assets (One-Time Capital Event)	$14,000,000	Acquisition price by CONMED Corporation in early 2024.
Interest Income on Remaining Cash Balance	Not explicitly reported for 2025	Last reported cash and equivalents balance was $4.9 million as of March 31, 2024.
Minimal Residual Revenue (Inventory/Equipment)	Not explicitly reported for 2025	This would represent final wind-down sales, if any, post-acquisition.

The old model, reliant on consumables, is confirmed to be obsolete for the entity Motus GI Holdings, Inc. as an independent operator:

• The old revenue from disposable sleeves (Q1 2024 was only $64,000) is now gone.

To be fair, that Q1 2024 sleeve revenue of $64,000 was the last gasp of the razor-and-blade component of the business model before the Chapter 7 filing and asset sale.

The structure of the final capital event is key to understanding the current financial state, which is now tied to the proceeds of that transaction:

• The asset sale to CONMED Corporation for approximately $14 million in Q1 2024 provided the main source of current capital.
• The cash and cash equivalents balance as of March 31, 2024, was $4.9 million.
• Net cash used in operating activities for the three months ended March 31, 2024, was $2.0 million.

Finance: draft 13-week cash view by Friday.